Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Since only 3 subjects were enrolled in this study, the efficacy data is not interpretable and will not be presented. Only Adverse Event (AE) data will be summarized in a table, with frequency counts and percentages.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with adult-onset Rheumatoid Arthritis (RA) \>6 months and \<3 years
Active RA
Must have failed at least one disease modifying Anti Rheumatic Drug (DMARD) treatment
Subject can have attempted no more than one previous Anti Tumor Necrosis factor (anti-TNF) and discontinued due to drug intolerance
You may not be if
Subject cannot have a second non-inflammatory musculoskeletal condition
Subject cannot have a diagnosis of any other inflammatory arthritis
Subject cannot have any previously infected prosthesis
Subject cannot have arthroplasties in any of the joints assessed in the study
Subject cannot have a history of chronic infections
Subject cannot have known Tuberculosis (TB) disease, high risk of acquiring TB, or latent TB infection
Subject cannot have a history of or current Lymphoproliferative disorder
Subject cannot have known Human Immunodeficiency Virus (HIV) infection
Subject cannot have received a live or attenuated vaccine within 8 weeks
Subject cannot have current or history of malignancy
Subject cannot have a history of blood disorders
Subject cannot have a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease
Subjects must not have a history of adverse reaction to Polyethylene glycol (PEG), a protein medicinal product, or ultrasound gel applied to the skin
